Quality of life among testis cancer survivors

Gilligan, Timothy D.

doi:10.1016/j.urolonc.2015.05.018

Cited by 19 publications

(16 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tinnitus is a common condition, especially in cancer treatment, caused by chemotherapy drugs and radiotherapy [17,[20][21][22]. The present study did not reveal relation between tinnitus and hearing loss, in contrast investigators have reported this relation [20].…”

Section: Discussioncontrasting

confidence: 90%

Cancer treatment: changes in hearing thresholds

Machado¹,

Amaral²,

Aguiar³

et al. 2018

Oncol Res Rev

View full text Add to dashboard Cite

Purpose: Evaluate changes in hearing thresholds in patients undergoing cancer treatment.Method: Prospective, longitudinal study carried out at Cancer Center of a Sergipe´s public hospital, Brazil. Audiological evaluation (Conventional Pure Tone Audiometry) have been performed in 20 patients following eight weeks of cancer treatment (reference exam) and 20 weeks (sequential exam) of treatment. All survivors had normal hearing thresholds before cancer treatment. The procedure has been approved by the Ethics in Research Committee, under protocol # 33665014.7.0000.5546.Results: Head and neck cancer displayed oncology highest incidence (35%). Referential exam, eight weeks before treatment, displayed 15% with sensorineural hearing loss and 17.5% at second tests. It was observed a slight worsening for all test frequencies of referential and sequential exam. Tinnitus was the biggest complaint (81.3%), but there was no statistic correlation between hearing loss (p=0.89). Conclusion:Hearing monitoring form this small sample suggest chemotherapy and radiotherapy treatments can have a detrimental effect on hearing thresholds significate for 2 to 8kHz eight weeks after cancer treatment and 4 to 8kHz 20 weeks before.

show abstract

Section: Discussioncontrasting

confidence: 90%

Cancer treatment: changes in hearing thresholds

Machado¹,

Amaral²,

Aguiar³

et al. 2018

Oncol Res Rev

View full text Add to dashboard Cite

show abstract

“…chemotherapy, radiation, etc. ), previously noted, are discussed by Gilligan (2015) . The authors indicate that later-stage cases treated with chemotherapy experience a significantly worse quality of life and manifest higher frequencies of adverse mental health outcomes as compared to their counterparts diagnosed early in the staging process.…”

Section: Inconsistencies In Logic Language and Methodologymentioning

confidence: 74%

“…The USPSTF (2011) states that males typically detect TCa unintentionally or through self/partner examination. Other research suggests that the best outcomes for TCa treatment stem from cases treated in earlier stages of the disease (see Saab et al, 2014 , Gilligan, 2015 , Öztürk et al, 2015 ). It would therefore be logical to assume that TSE or clinician examination promotes optimal wellness within this population.…”

Section: Inconsistencies In Logic Language and Methodologymentioning

confidence: 99%

From ‘D’ to ‘I’: A critique of the current United States preventive services task force recommendation for testicular cancer screening

Rovito

Manjelievskaia

Leone

et al. 2016

Preventive Medicine Reports

View full text Add to dashboard Cite

In 2004, the United States Preventive Services Task Force (USPSTF) gave testicular cancer (TCa) screening a ‘D’ recommendation, discouraging the use of this preventive service. The USPSTF suggested that screening, inclusive of testicular self-examination (TSE) and clinician examination, does not reduce TCa mortality rates and that the high risk of false positives could serve as a detriment to patient quality of life. Others suggests that TCa screening is ineffective at detecting early-stage cases of TCa and readily highlights a lack of empirical evidence demonstrating said efficacy. These assertions, however, stand in stark contrast to the widely held support of TCa screening among practicing public health professionals, advocacy groups, and clinicians.In this present study, a review was conducted of the methods and processes used by the USPSTF in their 2011 reaffirmation of the ‘D’ grade recommendation. The evidence base and commentary offered as to why TSE, as part of the overall recommendation for TCa screening, was given a ‘D’ grade were analyzed for logical reasoning and methodological rigor.Considering the methodological flaws and the veritable lack of evidence needed to grant a conclusive recommendation, the question is raised if the current ‘D’ grade for TCa screening (i.e. discourage the use of said service) should be changed to an ‘I’ statement (i.e. the balance of benefits and harms is indeterminate). Therefore the purpose of this paper is to present the evidence of TCa screening in the context of efficacy and prevention in order for the field to reassess its relative value.

show abstract

“…Depending on risk status, patients may receive systemic chemotherapy which typically incorporates bleomycin, etoposide, and cisplatin (BEP). Prognosis is excellent with a 5-year relative survival rate for males in late adolescence and early adulthood of approximately 96% [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Malignant Transformation of Testicular Teratoma to PNET, Adenocarcinoma, and Osteosarcoma with Complete Remission after Surgery and Combination Chemotherapy in a Young Adult Male

Shaw

Morrell

Weissferdt

et al. 2018

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Mixed germ cell tumors (GCT) with teratoma components can transform into somatic malignancies which can include histologies outside of traditional germ cell lineages. We describe a case of an 18-year-old man with a metastatic testicular GCT with both mature and immature teratoma components containing malignant transformation into multiple histologies including PNET in the primary testicular tumor and osteosarcoma in a separate pulmonary metastatic lesion. Management with targeted chemotherapy resulted in a durable remission. This is the first reported case that we know of a patient with primary PNET malignant transformation with subsequent metastatic transformation to osteosarcoma.

show abstract

Quality of life among testis cancer survivors

Cited by 19 publications

References 60 publications

Cancer treatment: changes in hearing thresholds

Cancer treatment: changes in hearing thresholds

From ‘D’ to ‘I’: A critique of the current United States preventive services task force recommendation for testicular cancer screening

Malignant Transformation of Testicular Teratoma to PNET, Adenocarcinoma, and Osteosarcoma with Complete Remission after Surgery and Combination Chemotherapy in a Young Adult Male

Contact Info

Product

Resources

About